FORMULATION AND EVALUATION OF CYCLODEXTRIN-BASED CURCUMIN NANOPARTICLES
Main Article Content
Keywords
nanoparticles, cyclodextrins, cancers, curcumin and nanosystems
Abstract
Malignant breast tumors accounted for 28% of recent instances and 15% of deaths within the United States of America in 2010. in addition, breast ailment is the maximum common disease amongst Iranian ladies, accounting for 24.4% of all illnesses malignancies and 3.3% of deaths in step with thousand. The sickness seemed global and killed 25 people 5 % of all cancers. Nanoparticles and their use inside the detection, imaging, drug transport and remedy of malignant breast tumors have been carried out. even though using nanoparticles in formulations nonetheless has issues and limitations, it is was hoping that nanoparticles can wreak havoc in oncology and medicinal drug in the near destiny. most suitable nanosystems with stepped forward solubility and optimized dissolution charges through supporting poorly soluble anti-cancer pills on nanoparticles
Downloads
References
1. Priyadarsini KI. The chemistry of curcumin: from extraction to a therapeutic agent. Molecules 2014; 19:20091-20112. 2. Gupta SC, Sung B, Kim JH, Prasad S, Li S, Aggar-wal BB. Multitargeting by turmeric, the golden spice: from the kitchen to clinic. Mol Nutr Food Res 2013; 57:1510-1528. 3. Vogel H, Pelletier J. Curcumin-biological and Medici-nal properties. J Pharmacie 1815; 1:289. 4. Lüer SC, Goette J, Troller R, Aebi C. Synthetic ver-sus natural curcumin: bioequivalence in an in vitro oral mucositis model. BMC Complement Altern Med 2014; 14:53. 5. Singh S. From exotic spice to modern drug? Cell 2007; 130:765-768. 6. Hatcher H, Planalp R, Cho J, Torti FM, Torti SV. Cur-cumin: from ancient medicine to current clinical tri-Cell Mol Life Sci 2008; 65:1631-1652. 7. Qin F, Huang X, Zhang HM, Ren P. Pharmacokinetic comparison of puerarin oral administration of Jiawei-Xiaoyao-San to healthy volunteers and pa-patients with functional dyspepsia: in the science of disease state. J Pharm Pharmacol 2009; 61:125-129. 8. Hongyu Zhou, Beevers CS, Shile Huang. Targets of curcumin. Curr Drug Targets 2011; 12:332-347. 9. Prasad S, Gupta SC, Tyagi AK, Aggarwal BB. Cur-cumin, a component of golden spice: from bedside to bench and back. Biotechnol Adv 2014; 32:1053-1064. 10. Attari, E., Nosrati, H., Danafar, H., &KheiriManjili, H. (2019). Methotrexate anticancer drug delivery to breast cancer cell lines by iron oxide magnetic based nanocarrier. Journal of Biomedical Materials Research Part A, 107(11), 2492-2500. 11. Jin S, Ye K. Targeted drug delivery for breast cancer treatment. Recent patents on anti-cancer drug discovery. 2013 May 1;8(2):143-53. 12. R Mokoena, D., P George, B., &Abrahamse, H. (2019). Enhancing Breast Cancer Treatment Using a Combination of Cannabidiol and Gold Nanoparticles for Photodynamic Therapy. International Journal of Molecular Sciences, 20(19), 4771. 13. Singh, S. K., Singh, S., LillardJr, J. W., & Singh, R. (2017). Drug delivery approaches for breast cancer. International journal of nanomedicine, 12, 6205. 14. Vinothini, K., Rajendran, N. K., Ramu, A., Elumalai, N., &Rajan, M. (2019). Folate receptor targeted delivery of paclitaxel to breast cancer cells via folic acid conjugated graphene oxide grafted methyl acrylate nanocarrier. Biomedicine & Pharmacotherapy, 110, 906-917. 15. Adhyapak AA, Desai BG. Formulation and evaluation of liposomal transdermal patch for targeted drug delivery of tamoxifen citrate for breast cancer. Indian Journal of Health Sciences and Biomedical Research (KLEU). 2016 Jan 1;9(1):40. 16. Barani M, Mirzaei M, Torkzadeh-Mahani M, Adeli-Sardou M. Evaluation of Carum-loaded Niosomes on Breast Cancer Cells: Physicochemical Properties, In Vitro Cytotoxicity, Flow Cytometric, DNA Fragmentation, and Cell Migration Assay. Scientific reports. 2019 May 9;9(1):1-0. 17. Harris JR, Lippman ME, Veronesi U, Willett W. Breast cancer. New England Journal of Medicine. 1992 Jul 30;327(5):319-28. 18. Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB, Edge SB, Erban JK, Farrar sWB, Goldstein LJ, Gradishar WJ, Hayes DF. Breast cancer. Journal of the National Comprehensive Cancer Network. 2009 Feb 1;7(2):122-92. 19. Sandhya P. Development and Evaluation of Lapatinib Solid Lipid Nanoparticles in the Management of Breast Cancer. International Journal of Pharmaceutical Sciences and Drug Research. 2019;11(5):245-9. 20. Asghari F, Khademi R, Ranjbar FE, Malekshahi ZV, Majidi RF. Application of Nanotechnology in Targeting of Cancer Stem Cells: A Review. International Journal of Stem Cells. 2019;12(2):227. 21. Thagele R, Kori ML. Formulation Development and Characterization of Targeted Drug Delivery System for Breast Cancer. Journal of Pharmaceutical Sciences and Research. 2017 Aug 1;9(8):1388. 22. Liyanage PY, Hettiarachchi SD, Zhou Y, Ouhtit A, Seven ES, Oztan CY, Celik E, Leblanc RM. Nanoparticle-mediated targeted drug delivery for breast cancer treatment. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer. 2019 Apr 1;1871(2):419-33. 23. Di Wu MS, Xue HY, Wong HL. Nanomedicine applications in the treatment of breast cancer: current state of the art. International journal of nanomedicine. 2017; 12:5879. 24. Navya PN, Kaphle A, Srinivas SP, Bhargava SK, Rotello VM, Daima HK. Current trends and challenges in cancer management and therapy using designer nanomaterials. Nano Convergence. 2019 Dec 1;6(1):23. 25. Dadras P, Atyabi F, Irani S, Ma'mani L, Foroumadi A, Mirzaie ZH, Ebrahimi M, Dinarvand R. Formulation and evaluation of targeted nanoparticles for breast cancer theranostic system. European Journal of Pharmaceutical Sciences. 2017 Jan 15; 97:47-54. 26. Tang X, Loc WS, Dong C, Matters GL, Butler PJ, Kester M, Meyers C, Jiang Y, Adair JH. The use of nanoparticles to treat breast cancer. Nanomedicine. 2017 Oct;12(19):2367-88. 27. Richie RC, Swanson JO. Breast cancer: a review of the literature. JOURNAL OF INSURANCE MEDICINE-NEW YORK THEN DENVER--. 2003 Jan 1;35(2):85-101. 28. Majeed W, Aslam B, Javed I, Khaliq T, Muhammad F, Ali A, Raza A. Breast cancer: major risk factors and recent developments in treatment. Asian Pac J Cancer Prev. 2014 Jan 1;15(8):3353-8. 29. Anjum F, Razvi N, Masood MA. Breast cancer therapy: a mini-review. MOJ Drug Des Develop Ther. 2017;1(2):00006. 30. Tanaka T, Decuzzi P, Cristofanilli M, Sakamoto JH, Tasciotti E, Robertson FM, Ferrari M. Nanotechnology for breast cancer therapy. Biomedical microdevices. 2009 Feb 1;11(1):49-63. 31. Yezhelyev MV, Gao X, Xing Y, Al-Hajj A, Nie S, O'Regan RM. Emerging use of nanoparticles in diagnosis and treatment of breast cancer. The lancet oncology. 2006 Aug 1;7(8):657-67. 32. Avitabile E, Bedognetti D, Ciofani G, Bianco A, Delogu LG. How can nanotechnology help the fight against breast cancer? Nanoscale. 2018;10(25):11719-31. 33. Misra R, Acharya S, Sahoo SK. Cancer nanotechnology: application of nanotechnology in cancer therapy. Drug discovery today. 2010 Oct 1;15(19-20):842-50. 34. Jain V, Kumar H, Anod HV, Chand P, Gupta NV, Dey S, Kesharwani SS. A review of nanotechnology-based approaches for breast cancer and triple-negative breast cancer. Journal of Controlled Release. 2020 Jul 10. 35. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nature reviews cancer. 2005 Mar;5(3):161-71. 36. Tran P, Lee SE, Kim DH, Pyo YC, Park JS. Recent advances in nanotechnology for the delivery of anticancer drugs for breast cancer treatment. Journal of Pharmaceutical Investigation. 2020 May;50(3):261-70. 37. Falagan-Lotsch P, Grzincic EM, Murphy CJ. New advances in nanotechnology-based diagnosis and therapeutics for breast cancer: an assessment of active-targeting inorganic nanoplatforms. Bioconjugate chemistry. 2017 Jan 18;28(1):135-52. 38. Gadade DD, Pekamwar SS. Cyclodextrin-based nanoparticles for drug delivery and theranostics. Advanced pharmaceutical bulletin. 2020 Jun;10(2):166. 39. Sivakumar PM, Peimanfard S, Zarrabi A, Khosravi A, Islami M. Cyclodextrin-based nanosystems as drug carriers for cancer therapy. Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Cancer Agents). 2020 Jul 1;20(11):1327-39.
Article Sidebar
Published
May 25, 2023
Article Details
How to Cite
1.
Anup M.Akarte1*, Prakash H.Patil2
FORMULATION AND EVALUATION OF CYCLODEXTRIN-BASED CURCUMIN NANOPARTICLES
. 2023 Mar. 13;94(1): 1774-1786 . Available from: https://mattioli.1885journals.com/article/2023/1774.html
Issue
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.